Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Heparin Tolerability Study
NCT04490239Phase 1Completed
- Start
- Oct 2020
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of heparin in coronavirus disease 2019 (COVID-19). Primary endpoints: Activated Partial Thromboplastin Time, Platelet Count and 1 more. Started Oct 2020; status: completed.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04490239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04490239.